Peptide-Based Anti-PCSK9 Product for Long-Lasting Management of Hypercholesterolemia
Vaccines · 22.08.2025 · 13 (9) · 889
DOI: 10.3390/vaccines13090889 ↗Kurz gefasst
Fachartikel in der Zeitschrift Vaccines, online erschienen am 22.08.2025. Verfasst von Suresh R Giri und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, Zydus Research Centre, Zydus Lifesciences Ltd., Ahmedabad 382213, India. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Zydus Life sciences Ltd..
Abstract (Originalsprache)
Background/Objectives: Hypercholesterolemia remains a major risk factor for cardiovascular disease and a leading cause of global mortality. Proprotein convertase subtilisin/kexin type 9 (PCSK9) promotes degradation of low-density lipoprotein receptors (LDLR), thereby reducing LDL-cholesterol (LDL-C) clearance. While monoclonal antibodies (mAbs) targeting PCSK9 are effective, their short half-life requires frequent dosing and incurs high treatment costs. This study evaluates a novel peptide-based Anti-PCSK9 product aimed at providing sustained LDL-C reduction.
Methods
A novel PCSK9 based-peptide conjugated to diphtheria toxoid (DT) was evaluated in various preclinical models: high-fat diet-fed C57BL/6 mice, APOB100/hCETP transgenic mice, BALB/c mice and normocholesterolemic non-human primates. Immunogenicity (Anti-PCSK9 antibody titers, binding affinity by SPR), pharmacodynamics (LDL-C levels, inhibition of PCSK9-LDLR interaction) and safety were assessed. Toxicity was evaluated in rodents, rabbits and dogs through clinical monitoring, histopathology, organ function and safety pharmacology studies.
Results
The Anti-PCSK9 product induced robust and long-lasting immune response in all models antibody titers in BALB/c mice peaked by week 6 and persisted for 12 months. LDL-C reductions of 44% in APOB100/hCETP mice and 37% in C57BL/6 mice correlated with high antibody titers and strong PCSK9-binding affinities (85 and 49 RU), leading to 59% and 58% inhibition of PCSK9-LDLR interaction, respectively. Non-human primates showed sustained responses. No systemic toxicity was observed; injection-site reactions were mild and reversible. No adverse effects were detected on cardiovascular, neurological, or respiratory systems.
Conclusions
This peptide-based Anti-PCSK9 therapy offers sustained efficacy and safety, representing a promising long-acting alternative for managing hypercholesterolemia.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacology and Toxicology, Zydus Research Centre, Zydus Lifesciences Ltd., Ahmedabad 382213, India.
- Department of Cell Biology, Zydus Research Centre, Zydus Lifesciences Ltd., Ahmedabad 382213, India.
- Department of Biotechnology, Zydus Research Centre, Zydus Lifesciences Ltd., Ahmedabad 382213, India.
- Department of Medicinal Chemistry, Zydus Research Centre, Zydus Lifesciences Ltd., Ahmedabad 382213, India.
ORCID-Profile: Suresh R Giri, Akshyaya Chandan Rath, Vighnesh N Jadhav, Mukul R Jain
Förderung
- Zydus Life sciences Ltd.
Zitieren
APA
Giri, S. R., Rath, A. C., Trivedi, C. J., Bhoi, B. B., Palode, S. R., Jadhav, V. N., Bhayani, H., Singh, A., Patel, C., Patel, T. M., Sakhrani, N. M., Patel, J. H., Shah, N. A., Chopade, R., Bahekar, R., Pawar, V., Sundar, R., Bandyopadhyay, S., & Jain, M. R. (2025). Peptide-Based Anti-PCSK9 Product for Long-Lasting Management of Hypercholesterolemia. Vaccines, 13(9), 889. https://doi.org/10.3390/vaccines13090889
Vancouver
Giri SR, Rath AC, Trivedi CJ, Bhoi BB, Palode SR, Jadhav VN, et al. Peptide-Based Anti-PCSK9 Product for Long-Lasting Management of Hypercholesterolemia. Vaccines. 2025;13(9):889. doi:10.3390/vaccines13090889
BibTeX
@article{Giri2025,
author = {Giri, Suresh R and Rath, Akshyaya Chandan and Trivedi, Chitrang J and Bhoi, Bibhuti Bhusan and Palode, Sandip R and Jadhav, Vighnesh N and Bhayani, Hitesh and Singh, Avanishkumar and Patel, Chintan and Patel, Tushar M and Sakhrani, Niraj M and Patel, Jitendra H and Shah, Niraj A and Chopade, Rajendra and Bahekar, Rajesh and Pawar, Vishwanath and Sundar, Rajesh and Bandyopadhyay, Sanjay and Jain, Mukul R},
title = {Peptide-Based Anti-PCSK9 Product for Long-Lasting Management of Hypercholesterolemia},
journal = {Vaccines},
year = {2025},
volume = {13},
number = {9},
pages = {889},
doi = {10.3390/vaccines13090889}
}
EUVIMED